Time to Consider the Compromised!



As COVID-19 restrictions lift and life returns to a new normal for many in society, the lives of immunocompromised (IC) blood cancer patients remain at risk since more than 1 in 4 do not produce antibodies against COVID-19 even after a full course of vaccinations.

These patients carry a high risk of infection, severe disease course and death, and suffer from psychological side-effects due to prolonged shielding.

How can YOU as a researcher help to keep them safe?

The International Covid-19 Blood Cancer Coalition calls on you to

1. Enable and encourage specific research about COVID-19 and IC blood cancer patients and existing and future antiviral and monoclonal antibody treatments.
2. Accelerate clinical trials for these next-generation antiviral and antibody treatments.

In their joint statement, more than 70 researchers, clinicians, patient organisations and medical societies urge stakeholders to consider IC blood cancer patients in health policy decisions.

Thank you for helping to protect those who cannot protect themselves.

About the ICBCC:
A multi-stakeholder coalition, the International COVID-19 Blood Cancer Coalition, calls upon decision-makers in health policy and care to enable access to IC blood cancer patients to life-saving therapies, and to drive change to accommodate the needs of those patients in general and particularly during the COVID-19 pandemic.

ICBCC
International COVID-19 Blood Cancer Coalition

Find out more at icbcc.info

#considerthecompromised #icbcc